Table 1—

Effect of ACEIs and ARBs on cardiovascular end points

End pointn (studies)n (patients)OR (95% CI)
Mortality
    All studies11109,0520.96 (0.91–1.01)
    ACEI only674,6260.95 (0.88–1.03)
    ARB only534,4260.96 (0.89–1.03)
    HTN studies786,4141.00 (0.95–1.04)
    CAD studies217,5870.85 (0.77–0.94)
    HF studies25,0510.94 (0.79–1.12)
Cardiovascular mortality
    All studies11109,0520.93 (0.86–1.01)
    ACEI only674,6260.93 (0.81–1.06)
    ARB only534,4260.93 (0.85–1.01)
    HTN studies786,4140.99 (0.93–1.06)
    CAD studies217,5870.82 (0.64–1.06)
    HF studies25,0510.91 (0.76–1.08)
Stroke
    All studies11109,0520.95 (0.81–1.12)
    ACEI only674,6260.97 (0.80–1.18)
    ARB only554,1411.04 (0.82–1.32)
    HTN studies786,4141.04 (0.86–1.26)
    CAD studies217,5870.70 (0.59–0.84)
    HF studies25,0510.89 (0.67–1.18)
MI
    All studies967,4050.96 (0.83–1.12)
    ACEI only432,9790.83 (0.73–0.94)
    ARB only534,4261.11 (0.93–1.32)
    HTN studies653,0570.98 (0.85–1.14)
    CAD studies19,2970.79 (0.69–0.89)
    HF studies25,0511.11 (0.54–2.29)
Fatal MI
    All studies670,2660.92 (0.82–1.04)
    ACEI only565,3290.92 (0.82–1.04)
    ARB only14,9370.99 (0.52–1.91)
    HTN studies561,9760.88 (0.76–1.02)
    CAD studies18,2901.00 (0.83–1.21)
    HF studies0Not estimable
Nonfatal MI
    All studies428,6190.92 (0.75–1.13)
    ACEI only323,6820.87 (0.69–1.11)
    ARB only14,9371.14 (0.77–1.70)
    HTN studies428,6190.92 (0.75–1.13)
    CAD studies0Not estimable
    HF studies0Not estimable
  • CAD, coronary artery disease; HF, heart failure; HTN, hypertension; MI, myocardial infarction.